Bullish indicating open at $55-$60, IPO prices at $37
Investing.com -- Vimian Group AB (STO:VIMIAN) reported second-quarter results below expectations, with adjusted EBITA of EUR 25.4 million, missing analyst consensus by 7%.
The animal health company posted net sales of EUR 104.3 million, up 15% year-over-year but 2% below Modular Finance consensus estimates.
The revenue miss was primarily due to weaker-than-expected performance in the Specialty Pharma and MedTech segments.
Adjusted EBITA grew 3% year-over-year, with margins contracting to 24.3% from 27.2% in the same period last year. Analysts had expected a margin of 25.4%.
The company achieved 5% organic growth at the group level, with Specialty Pharma growing 6%, Veterinary Services 12%, and Diagnostics 18%.
These gains were partially offset by a 4% organic decline in MedTech, which the company attributed to a continued soft US surgery market.
By segment, Specialty Pharma generated EUR 45.3 million in revenue (+4% year-over-year) with an adjusted EBITA margin of 30.0%, slightly up from 29.7% last year.
MedTech revenue reached EUR 37.1 million (+32% year-over-year), but its adjusted EBITA margin fell significantly to 23.7% from 31.6% in the second quarter of 2024.
Veterinary Services posted EUR 16.2 million in revenue (+12% year-over-year) with an improved margin of 28.7%, up from 27.6%.
The Diagnostics segment generated EUR 5.7 million (+16% year-over-year) with a margin of 9.2%, compared to 8.2% in the prior year period.
In a separate development, Vimian announced the departure of its CEO, with CFO Carl-Johan Zetterberg Boudrie appointed as interim CEO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.